非小细胞肺癌免疫检查点抑制剂应答的预测性生物标志物
本综述讨论晚期非小细胞肺癌(NSCLC)中免疫检查点阻断的预测性生物标志物,包括肿瘤PD-L1表达的用途与局限,以及肿瘤突变负荷、肿瘤微环境和宿主免疫系统相关因素等新兴策略,并涉及外周血监测等新型检测方法。
要点
- 肿瘤PD-L1表达作为预测性生物标志物存在使用局限。
- 新兴生物标志物包括肿瘤突变负荷、肿瘤微环境和宿主免疫系统相关因素。
- 外周血监测等新型生物标志物检测方法也在综述范围内。
核心结论
- 需要额外的预测性生物标志物来改善患者选择并避免潜在无应答者的毒性。
研究设计与样本
- 综述,讨论晚期非小细胞肺癌免疫检查点阻断的预测性生物标志物。
主要发现
- 免疫检查点阻断在部分晚期NSCLC患者中观察到持久抗肿瘤活性和生存改善。
- 综述涉及肿瘤PD-L1表达作为预测性生物标志物的使用与局限。
- 综述涉及肿瘤突变负荷、功能缺失与功能获得性激活突变等遗传改变。
- 综述涉及肿瘤微环境等肿瘤相关因素及宿主免疫系统相关因素。
- 综述涉及外周血监测等新型生物标志物检测方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.
引用
- Prelaj A, Tay R, Ferrara R, et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2018. PMID: 30528799. doi:10.1016/j.ejca.2018.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。